Clinical safety of the selective PKC-β inhibitor, ruboxistaurin
Janet B. McGill(Washington University in St. Louis), David L. Hyslop(Eli Lilly (United States)), Keri A. Kles(Eli Lilly (United States)), Paul H. Berg(Eli Lilly (United States)), Edward J. Bastyr(Eli Lilly (United States)), Karen Price(Eli Lilly (United States)), George L. King(Joslin Diabetes Center)
Cited by 48
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
|Circulation Research|2010|979